TrialBlood advances2022

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial.

Annoek E C Broers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.